<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ALTU</title>
	<atom:link href="http://www.stockbloghub.com/tag/altu/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Begins Mid-Stage Trial</title>
		<link>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916</link>
		<comments>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916#comments</comments>
		<pubDate>Wed, 23 Sep 2009 19:42:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALTU]]></category>
		<category><![CDATA[Altus Pharmaceuticals Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15916</guid>
		<description><![CDATA[Yesterday, BioMarin Pharmaceutical Inc. (BMRN) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria (PKU). The company expects initial results from the study in mid-2010. It is co-developing the candidate with Merck Serono (MRK). The primary objective of the open-label, multi-center study, to be conducted in up to 35 patients, is to evaluate the effect of PEG-PAL on blood phenylalanine (Phe) concentrations in PKU patients. The secondary objectives are to evaluate its safety and tolerability, immune response and steady state pharmacokinetics of subcutaneous injections of multiple dose levels. BioMarin, which competes with companies such as Enzon Pharmaceuticals Inc. (ENZN), Shire Plc (SHPGY) and Altus Pharmaceuticals Inc. (ALTU), already has Kuvan in the market for treating PKU. The primary difference between PEG-PAL and Kuvan is the mode ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

